Clinical Trials Logo

Filter by:
NCT ID: NCT05436925 Active, not recruiting - Hyperglycemia Clinical Trials

CGM Use in Preterm Infants

Start date: October 3, 2022
Phase:
Study type: Observational

Preterm infants (gestational age (GA) at birth < 31 weeks) admitted to the University of Minnesota Masonic Children's Hospital NICU will have a Dexcom G6 sensor Continuous Glucose Monitor (CGM) placed shortly after consent and wear the device for up to 10 days. The low alarm threshold will be set at 60 mg/dL or 80mg/dL (depending on whether they are receiving continuous insulin) to detect the potential for hypoglycemia. A suggestion will be made to the clinical team to draw a blood glucose to correlate with CGM values ≤60 mg/dL and the infant will be treated according to Neonatal Intensive Care Unit (NICU) protocol for corroborating blood glucose levels. Infants will also be monitored per current NICU protocol (blood glucose checks every 1-2 hours while on insulin) and treated accordingly. Clinical data and long-term growth, body composition and neurodevelopmental outcomes will be recorded.

NCT ID: NCT05436639 Active, not recruiting - Clinical trials for ACTH-Independent Cushing Syndrome

SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor

ACSPIRE
Start date: July 1, 2023
Phase: Phase 2
Study type: Interventional

This is study with SPI-62 to evaluate the efficacy, safety, and pharmacological effect of SPI-62 in subjects with hypercortisolism related to a benign adrenal tumor. Each subject will receive 2mg of SPI-62 daily.

NCT ID: NCT05436457 Active, not recruiting - Firearm Injury Clinical Trials

Clinical Screening for Firearm Violence Risk

Start date: July 26, 2021
Phase:
Study type: Observational

The purpose of the proposed work is to harness cutting-edge machine learning methods to optimize prediction of future firearm violence in youth ages 18-24 so that prevention resources can be allocated efficiently.

NCT ID: NCT05436145 Active, not recruiting - Depression Clinical Trials

Intern Health Study 2022 and 2023

IHS
Start date: July 1, 2022
Phase: N/A
Study type: Interventional

The aim of this trial is to evaluate the efficacy of an intervention (delivered through a smartphone) for improving the mood, physical activity, and sleep of medical interns.

NCT ID: NCT05434741 Active, not recruiting - HIV Clinical Trials

Cognitive Behavior Therapy (CBT)-Based Group Intervention to Reduce Inflammation in Older People With HIV

CHAMP
Start date: June 20, 2022
Phase: N/A
Study type: Interventional

In this study, the investigators will assess the feasibility and acceptability of an evidence-based CBT group intervention, developed for older people with HIV, and research methods in a pilot randomized controlled trial including 50 older people with HIV as participants. The evidence-based CBT intervention has been developed and utilized in three clinical groups to date initiated and led by Dr. Batchelder (PI) in the Behavioral Medicine program at MGH. The 12-week intervention program proposed leverages evidence-based traditional and contemporary CBT strategies, with the goal of improving the psychological and physical functioning of older people with HIV by providing education and support to learn strategies to: a.) better manage stressors associated with HIV and aging (e.g., multi-morbidity), and b.) increase health-promoting behaviors (e.g., physical activity).

NCT ID: NCT05434663 Active, not recruiting - Clinical trials for Chemotherapy-Induced Nausea and Vomiting (CINV)

Safety Study of Repeat Doses of SUSTOL in Adults

Start date: July 6, 2022
Phase: Phase 4
Study type: Interventional

This is a repeat-dose, single-arm, open-label study that will evaluate the potential impact of subject-reported injection-site reactions (ISRs) on activities of daily living (ADL) in adult subjects with cancer receiving SUSTOL® (granisetron) extended-release injection, for subcutaneous use for prevention of chemotherapy induced nausea and vomiting (CINV) for up to 4 sequential cycles of chemotherapy (Moderately Emetogenic Chemotherapy [MEC] or Anthracycline and Cyclophosphamide [AC] combination regimen).

NCT ID: NCT05433584 Active, not recruiting - Type 2 Diabetes Clinical Trials

A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes

SURPASS-EARLY
Start date: August 1, 2022
Phase: Phase 4
Study type: Interventional

This study aims to investigate the efficacy and safety of tirzepatide in participants with type 2 diabetes (T2D) compared to other existing treatment options when treatment is initiated early.

NCT ID: NCT05432193 Active, not recruiting - Colorectal Cancer Clinical Trials

FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)

Start date: July 13, 2022
Phase: Phase 1
Study type: Interventional

This Phase 1 study will evaluate the safety and tolerability of [Ga-68]-PNT6555 and [Lu-177]-PNT6555 in subjects with select solid tumors that have FAP over-expression, in order to determine a recommended Phase 2 dose.

NCT ID: NCT05432167 Active, not recruiting - Clinical trials for Chronic Kidney Diseases

A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease

Start date: April 29, 2022
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety of CIN-107 for the treatment of hypertension in patients with uncontrolled hypertension (uHTN) and Chronic Kidney Disease (CKD).

NCT ID: NCT05431166 Active, not recruiting - Loneliness Clinical Trials

Virtual Yoga for Social Isolation and Loneliness in Rural Veterans

Start date: October 1, 2021
Phase: N/A
Study type: Interventional

The overarching goal of this project is to decrease social isolation and loneliness through increased awareness and uptake of virtual yoga group classes among rural Veterans.